Skip to main content

About Daniel F. Kelly, MD

Daniel F. Kelly, MD is Founder and Director of Pacific Neuroscience Institute at Providence Saint John’s Health Center and Professor of Neurosurgery at John Wayne Cancer Institute (JWCI) in Santa Monica, CA. In practice for 25 years, Dr. Kelly is internationally recognized for his accomplishments in the field of minimally invasive and endoscopic keyhole surgery for brain, skull base and pituitary tumors. He has been awarded the Southern California SuperDoctors distinction 11 years in a row (2006-17).  His personal surgical series includes over 2000 endonasal transsphenoidal operations and almost 2000 operations for brain tumor. He has authored over 100 peer-reviewed publications and more than 40 book chapters on topics including surgical outcomes and techniques, patient satisfaction and complication avoidance for a wide range of brain, skull base and pituitary tumors. His research interests include refining and developing endonasal endoscopic and keyhole surgical approaches, enhancing post-operative quality of life and pituitary hormonal function, and identifying targetable biomarkers and other novel treatments for patients with intracranial tumors.
 
Dr. Kelly is an active member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the International Society of Pituitary Surgeons, the Pituitary Society, and the North American Skull Base Society, and a member of the editorial board of the journal Neurosurgery and World Neurosurgery. Dr. Kelly has a long-standing commitment to continuing medical education, fellowship training and patient education, and he lectures frequently at national and international meetings. Dr. Kelly is a graduate of Claremont McKenna College, Georgetown University School of Medicine and completed neurosurgical residency training in 1993 at George Washington University Medical Center. He was Professor of Neurosurgery and Vice-Chief of Clinical Affairs for the UCLA Division of Neurosurgery until 2007 when he joined JWCI and Providence Saint John’s Health Center, where he currently serves on the Saint John’s Board of Directors and is Chief of Neurosurgery. As Chairman of Pacific Neuroscience Institute Medical Group, he helps oversee and direct a multispecialty neuroscience program of 24 physicians across 9 subspecialties and 9 centers of excellence.

Positions

2016 - Present Chairman, Providence Pacific Neuroscience Institute Medical Group
to
2016 - Present Director and Founder, Providence Pacific Neuroscience Institute
to
2016 - Present President and CEO, Providence Pacific Neuroscience Institute Foundation
to
2014 - Present Member, Board of Directors, Providence Providence Saint John’s Health Center
to
2013 - Present Professor of Neuroscience & Neurosurgery, Providence John Wayne Cancer Institute
to
2010 - Present Chief, Providence Division of Neurosurgery, Saint John’s Health Center
to
2007 - Present Director, Providence Pacific Brain Tumor Center & Pituitary Disorders Center
to

Curriculum Vitae



Grants

2012 - 2015 A pilot study of pre- & post-operative Somatuline Depot therapy in acromegalic patients treated by endonasal endoscopic surgery: impact on early remission rate and perioperative morbidity
Ipsen
Role: Principal Investigator
2008 - 2012 Hypopituitarism in Retired Professional Football Players
National Operating Committee on Standards for Athletic Equipment (NOCSAE)
Role: Co-Principal Investigator
2006 - 2009 Rosiglitazone: novel therapy for pituitary tumors (Phase II)
NIH/FDA R01 - FD003096
Role: Co-Investigator
Colleague(s): Principal Investigator: Anthony Heaney MD, Ph.D
2002 - 2008 Hypopituitarism after Moderate and Severe Head Injury
NINDS/NIH - Grant # R01 NS 40777
Role: Principal Investigator
2002 - 2006 Acute Secondary Adrenal Insufficiency after Moderate and Severe Head Injury
NIH - Grant # K23 RR 1729801
Role: Co-Mentor
Colleague(s): Principal Investigator: Pejman Cohan, M.D
2002 - 2005 Hypopituitarism after Moderate and Severe Head Injury
Pfizer
Role: Principal Investigator
1998 - 2003 Project 1- “Incidence, Time Course, and Pathophysiology of Hyperglycolysis Following Human Traumatic Brain Injury”
UCLA Program Project Grant
Neurometabolic Pathobiology of Traumatic Brain Injury
Role: Co-Principal Investigator
Colleague(s): Program Director: Donald Becker, M.D.
2000 Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage
Pharmacia & Upjohn
Role: Principal Investigator
Colleague(s): Co-investigators: Pejman Cohan, M.D., Irene T. Gaw Gonzalo, M.D., Ronald Swerdloff, M.D. and Christina Wang, M.D.
1999 Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage
Stein-Oppenheimer Endowment Awards
Role: Principal Investigator
Colleague(s): Co-investigators: Ronald Swerdloff, M.D. Christina Wang, M.D., Irene T. Gaw Gonzalo, M.D., Mohammad Saad M.D.
1999 Post-traumatic Impairment of Cerebral Vasoreactivity
Zeneca Pharmaceuticals
Role: Principal Investigator
1998 Hypopituitarism Following Moderate and Severe Traumatic Brain Injury
Genentech Foundation for Growth and Development
Role: Co-Principal Investigator
Colleague(s): Co-investigators: Ronald Swerdloff, M.D. Christina Wang, M.D., Irene T. Gaw Gonzalo, M.D.
1997 - 1998 A Randomized Placebo-Controlled Study of CI-1009 in Severe Head Injury Patients
Parke-Davis Pharmaceuticals
Role: Principal Investigator
1993 - 1997 A randomized, stratified, double-blind, multi-center study of the efficacy and safety of Sygen vs placebo following standard methylprednisolone therapy in the treatment of acute spinal cord injury
Fidia Pharmaceutical Company
Role: Co-Investigator
Colleague(s): PI: Duncan McBride
1993 - 1997 Project 3 – “Post-Traumatic Cerebral Arterial Spasm
National Institute Neurologic Disease and Stroke
UCLA Brain Injury Research Center. Program Project Grant.
Role: Key Investigator
Colleague(s): Program Director: Donald P. Becker, M.D.
1996 Efficacy of 6 versus 10 mg of tirilazad mesylate in male patients with aneurysmal subarachnoid hemorrhage
The Upjohn Company
Role: Principal Investigator
1995 - 1996 Efficacy/Safety of 15 mg/kg/day Tirilazad Mesylate in North American Women with Subarachnoid hemorrhage
The Upjohn Company
Role: Principal Investigator
1994 - 1994 Dose escalation study of tirilazad mesylate in moderate and severe head injured patients
The Upjohn Company
Role: Principal Investigator
1993 - 1994 Dose escalation study of tirilazad mesylate in moderate and severe head injured patients
The Upjohn Company
Role: Co-investigator
Colleague(s): PI: Michael Caron
$
to
Enter a valid date range.

Professional Service and Affiliations

Member, American Association of Clinical Endocrinologists, Pituitary Scientific Committee
Member, American Association of Neurological Surgeons
Member, American Medical Association
Member, Congress of Neurological Surgeons
Member, Foundation for International Education in Neurological Surgery
Member, International Society of Pituitary Surgeons
Editorial Review Board, Ad hoc reviewer, Minimally Invasive Neurosurgery, Neuro-Oncology
Editorial Review Board, Neurosurgery
Member, North American Skull Base Society
Member, Society for Neuro-Oncology
Member, The Endocrine Society
Member, The Pituitary Society
Editorial Review Board, World Neurosurgery
to
Enter a valid date range.

Education

to
1993 Neurosurgical Residency Training, George Washington University Medical Center, Washington, D.C.
to
1987 Surgical Internship, St. Vincent's Hospital and Medical Center, New York, NY
to
1986 MD, Georgetown University ‐ School of Medicine
to
1982 BA, Claremont Men's College ‐ Biology and Chemistry
to


Research Works (237)